mdma
Washington (AFP) - A panel of US health experts convened by the Food and Drug Administration on Tuesday overwhelmingly voted against the use of MDMA, commonly known as ecstasy, to treat post-traumatic stress disorder. PTSD, a debilitating mental health condition that develops after a person experiences or is threatened by traumatic events such as death, combat or sexual assault, affects an estimated five percent of Americans in any given year. But pharmaceutical treatment options are so far limited to two antidepressants that require three months of dosing to take effect, and response rates t...
AFP
Washington (AFP) - A panel of US health experts convened by the Food and Drug Administration (FDA) are meeting Tuesday to weigh the benefits and risks of using MDMA, commonly known as ecstasy, to treat post-traumatic stress disorder. PTSD, a debilitating mental health condition that develops after a person experiences or is threatened by traumatic events such as death, combat, or sexual assault, affects an estimated five percent of Americans in any given year. But treatment options are so far limited to two antidepressants that require three months of dosing to take effect, and response rates...
AFP
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら